Novelix Pharma Q1 FY27 profit jumps 10x on 65% revenue growth

Revenue growth above 20%Profit growth above 25%Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.0%Reaction day

₹73.97

prior close

₹77.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+3.9% vs market

Healthcare Services peers, median of 61sector · industry level-0.4%+4.3% vs sector

On the reaction day the stock moved 3.9 pts more than Nifty Microcap 250 and 4.3 pts more than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

+0.8

15m

+0.8

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.0+0.1+3.9-0.4+4.3

Next day

-1.0+0.2-1.2-0.3-0.8

+3.1+0.6+2.6-0.2+3.4

+4.1-0.0+4.1-0.9+5.0

+5.0+0.5+4.5-0.9+5.9

+8.0+0.8+7.3-1.1+9.1

+9.4+0.6+8.8-0.2+9.6

15d

+5.4+1.3+4.2+0.6+4.9

+8.2-1.4+9.5-1.3+9.4

-11.5-0.6-10.9-7.9-3.6

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Services peers, median of 61Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Novelix Pharmaceuticals reported Q1 FY27 revenue of Rs 3,691.51 lakhs, up 65% YoY from Rs 2,235.12 lakhs. Profit after tax surged to Rs 117.89 lakhs from Rs 10.70 lakhs YoY. Basic EPS rose to Rs 0.49 from Rs 0.09. The firm operates in active pharmaceutical ingredients trading. Auditor issued a clean limited review report.

Likely market impact

Strong revenue and profit growth signal improving momentum for this small-cap pharma trader.